About
Antiphospholipid syndrome occurs worldwide with an estimated prevalence of 40 – 60 / 100.000. Women are affected more often than men. Whereas primary antiphospholipid syndrome (PAPS) occurs independently from other diseases, the more common secondary antiphospholipid syndrome (SAPS) is frequently related to other autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
Diagnosis
The diagnosis of antiphospholipid syndrome is based on the clinical symptoms and confirmed by laboratory methods. Laboratory confirmation of APS is generally performed by the determination of antibodies against phospholipids and phospholipid binding proteins. Although a range of different test systems based on various methods has been made available, the use of standardized ELISA-based immunoassays is recommended in the latest ACR / EULAR APS classification criteria 2023.
Sebia’s Expertise
Sebia offers the largest Alegria Monotest portfolio for random access determination of antibodies against various phospholipids (aPL) and phospholipid-binding proteins. A special proprietary antigen coating procedure and the use of human beta-2-glycoprotein I as a cofactor in Alegria aPL Monotests ensure reliable test results of the highest quality. Excellent accuracy, reproducibility and consistency of Alegria Monotests minimize the risk of misdiagnosis and inappropriate anti-coagulation treatment.
The ELISA-based Alegria Monotests are in compliance with the latest ACR/EULAR APS classification criteria 2023 and particularly suited for small series and offer a unique flexibility for maximum workflow efficiency with Alegria 2.
In addition to the Alegria Monotest portfolio, standard ELISA are available for higher sample throughput.
Featured resources on Antiphospholipid Syndrome
See all resourcesAlegria 2 properties and workflow
Obtain your patients results with high flexibility reliability and efficiency with Alegria 2.
Customer Testimonial about the Alegria 2
The Alegria 2 provides the possibility of giving results to clinicians within a timeframe fitting clinical needs and helps to optimize the patient’s care pathway.
Upcoming events
See all events
Antiphospholipid Syndrome
Unique accuracy in Antiphospholipid Syndrome Diagnostics.
Learn more about our unique technologies
- Barbhaiya et al. (2023) 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 82, 1258.
- Monogioudi et al. (2022) The certification of the concentration of anti-β2-glycoprotein I IgG in human serum: ERM-DA477/IFCC, EUR 31090 EN, Publications Office of the European Union, Luxembourg, 2022, ISBN 978-92-76-52954-5.
- Bradacova et al. (2021) Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines 9, 166.
- Volkov et al. (2020) Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto. Immun. Highlights. 11, 8.
- Devreese et al. (2018) Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J. Thromb. Haemost. 16, 809 – 13.
- Devreese et al. (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 12, 792.
- Lakos et al. (2012) International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 64, 1.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.